diabetes
AstraZeneca and Harvard team up for diabetes research
March 25, 2015Research and Development, Sales and Marketing AZ, AstraZeneca, Havard, cardiovascular, diabetes, metabolic
AstraZeneca is to work with Harvard University’s department of stem cell and regenerative biology to develop new treatments in diabetes. …
Lilly and Boehringer diabetes drug sees US launch
March 24, 2015Sales and Marketing Boehringer, Glyxambi, Tradjenta, diabetes, empagliflozin/linagliptin, lilly, linagliptin
Lilly and Boehringer Ingelheim’s combo diabetes drug Glyxambi is now available to treat adult patients in the US. Glyxambi (empagliflozin/linagliptin) …
Type 1 diabetes market value to double by 2023
March 19, 2015Research and Development, Sales and Marketing GlobalData, NHS, NICE, Sanofi, diabetes, toujeo, type 1
The treatment market for type 1 diabetes is set to double to around $13.6 billion by 2023 according to analysts …
Sanofi diabetes drug fails to show cardio disease benefit
March 19, 2015Research and Development, Sales and Marketing ACS, Lixisenatide, Lyxumia, Sanofi, cardio, diabetes
A Phase IIIb study of Sanofi’s diabetes drug lixisenatide has shown it is no better or worse than a placebo …
Sanofi sees FDA approval for diabetes drug
February 26, 2015Sales and Marketing Afrezza, FDA, Q2, Sanofi, Twitter, diabetes, insulin glargine, q4
US regulators have approved Sanofi’s diabetes treatment Toujeo which is said to be a follow-up to the French firms key …
Merck invests $450m in NGM Biopharma
February 23, 2015Sales and Marketing Merck, NGM Biopharma, NP201, diabetes, nonalcoholic steatohepatitis, obesity
Merck is to collaborate on drug development with biotech firm NGM Pharmaceuticals in a $450 million deal. The collaboration will …
Sanofi sales lifted by diabetes and rare diseases
February 6, 2015Sales and Marketing Genzyme, Lantus, Sanofi, diabetes, financials, insulin glargine, praluent, q4
Sanofi racked up €7.4 billion in sales in the fourth quarter of 2014 according to the company’s latest financials report. …
AstraZeneca looks for revenue boost via Actavis buy
February 6, 2015Sales and Marketing Actavis, AstraZeneca, Brilinta, Forxiga, diabetes, fourth quarter, q4
AstraZeneca recorded a dip in revenue in the last quarter of 2014 and is looking to ramp up its respiratory …
Needle-free device shows potential in diabetes
January 23, 2015Medical Communications, Sales and Marketing Cygnus, University of California, diabetes, tattoo
A ‘tattoo-like’ ultra-thin sensor that sits on the skin has been developed that could help patients monitor their blood glucose …
FDA approves novel obesity device
January 16, 2015Medical Communications, Sales and Marketing EnteroMedics, FDA, Novo, VBLOC, diabetes, obesity, type 2
The US Food and Drug Administration has shown the green light to US firm EnteroMedics’ new obesity device VBLOC that …
Sanofi and Boehringer partner on biologics manufacturing
January 15, 2015Manufacturing and Production, Sales and Marketing Boehringer, Sanofi, antibodies, biologics, cardiovascular, diabetes, mabs, manufacturing, monoclonal, oncology
Boehringer Ingelheim will help Sanofi extend its manufacturing capabilities for biologics in a new alliance, the companies have announced. Boehringer’s …
Novo Nordisk obesity drug gets FDA nod
December 24, 2014Sales and Marketing FDA, Novo Nordisk, Victoza, diabetes, liraglutide, saxenda
The US Food and Drug Administration has shown Novo Nordisk’s obesity drug Saxenda the green light to aid chronic weight …
NICE changes insulin advice in diabetes guidelines
December 12, 2014Sales and Marketing NHS, NICE, diabetes, health survey, insulin, type 1, type 2
NICE has changed its recommendations on type 1 diabetes in adults and children, and type 2 diabetes in children, to …
Roche buys Ariosa Diagnostics
December 2, 2014Research and Development, Sales and Marketing IPF, IQuum, InterMune, Roche, ariosa, cfdna, diabetes, genia, seragon
Roche has purchased the privately-held US company Ariosa Diagnostics for an undisclosed fee as it looks to expand further into …
